Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 66 pages report, published by Global Markets Direct

Keywords : Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Products under Development, Key Players in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Overview, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Assessment

Report ThumbnailSeptember-2013
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF). Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post-Polycythemia Vera Myelofibrosis (PPV-MF).
- A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2013 7
  • Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2013 7
  • Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Sanofi-Aventis, H2 2013 14
  • AstraZeneca PLC, H2 2013 15
  • Gilead Sciences, Inc., H2 2013 16
  • Novartis AG, H2 2013 17
  • Cell Therapeutics, Inc., H2 2013 18
  • Incyte Corporation, H2 2013 19
  • PharmaMar, S.A., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Drug Profile Updates 48
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) 7
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Products under Development by Companies 13
  • Companies Involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Development 14
  • Sanofi-Aventis 14
  • AstraZeneca PLC 15
  • Gilead Sciences, Inc. 16
  • Novartis AG 17
  • Cell Therapeutics, Inc. 18
  • Incyte Corporation 19
  • PharmaMar, S.A. 20
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • pacritinib - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • panobinostat - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • momelotinib - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • SAR-302503 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • plitidepsin - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • buparlisib - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • AUY-922 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • simtuzumab - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • INCB-39110 - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Drug Profile Updates 48
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 60
  • Featured News & Press Releases 60
  • Dec 07, 2012: Incyte Announces Presentation Of New Data For Jakafi At 2012 American Society Of Hematology Annual Meeting 60
  • Aug 28, 2012: Incyte's Partner Novartis Receives European Approval For Jakavi 61
  • Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting 61
  • May 16, 2012: Sanofi To Present Data On SAR302503 At 2012 American Society Of Clinical Oncology Annual Meeting 63
  • Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib 63
  • Appendix 65
  • Methodology 65
  • Coverage 65
  • Secondary Research 65
  • Primary Research 65
  • Expert Panel Validation 65
  • Contact Us 66
  • Disclaimer 66

Please select a license type

Share

Related Products

Global Markets DirectPost-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2013Product ThumbnailPost-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2013, Industry ReportProduct #: 113321
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved